Skip to content

News releases

The following are news releases and statements issued by Biosimilars Canada. News stories about biosimilars that may be of interest to readers are available here.

New Brunswick Becomes Third Province in Canada to Implement Biosimilar Switching Policy

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of New Brunswick for implementing a biosimilar “switching” or transitioning policy to expand the use of biosimilar medicines under the province’s public drug plans.
Read more

British Columbia Adds Humira Adalimumab to Biosimilar Switching Program

Biosimilars Canada today congratulated British Columbia and Health Minister Adrian Dix on the expansion of the province’s biosimilar switching program to include Humira adalimumab and a new indication for Enbrel etanercept.
Read more

Biosimilars Canada Announces Board Chair and Vice-Chair

Biosimilars Canada is pleased to announce the unanimous re-election of Mr. Michel Robidoux, President and General Manager of Sandoz Canada, as Chair of the Biosimilars Canada Board. Mr. Mike Woolcock, a Senior Vice President at Apobiologix, has been unanimously re-elected as Vice-Chair of the Biosimilars Canada Board.
Read more

CGPA / Biosimilars Canada Statement: COVID-19 and the Supply of Generic and Biosimilar Prescription Medicines to Canada’s Hospitals

Member companies of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada are working with our partners in government and the pharmaceutical supply chain to mitigate shortages of medicines used in Canada’s hospitals due to increases in demand resulting from the COVID-19 outbreak.
Read more

CGPA / Biosimilars Canada Statement on COVID-19 and the Supply and Distribution of Generic and Biosimilar Prescription Medicines in Canada

The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada continue to work closely with Health Canada, member companies and key stakeholders in the pharmaceutical supply chain to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines.
Read more

CGPA / Biosimilars Canada Statement on COVID-19 and the Supply and Distribution of Generic and Biosimilar Prescription Medicines in Canada

The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada continue to work closely with Health Canada, member companies and key stakeholders in the pharmaceutical supply chain to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines. To date, we are not aware of any drug shortages in Canada related to COVID-19.
Read more